Tulane Cancer Center
Dr. Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 peer-reviewed articles, led or co-led multiple national and international clinical studies, including three phase III studies pivotal for FDA approval. He has lectured widely, and at last count has given invited lectures in 33 countries.
He is currently the Associate Dean for Oncology, Medical Director of the Tulane Cancer Center, and serves as the Laborde Professor for Cancer Research at Tulane Medical School with appointments in both the Medicine and Urology Departments.
He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is past Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer, and is the Medical Oncology Chair of the GU committee of NRG, a national cancer research group. He is also a past member of the National Cancer Institute Board of Scientific Counselors (Clinical Sciences and Epidemiology) and is co-PI of the VISION trial, an international phase III study of Lu-177 PSMA in advanced prostate cancer.
Advanced Accelerator Applications (Individual(s) Involved: Self): Consultant, Grant/Research Support; Amgen (Individual(s) Involved: Self): Grant/Research Support; Astellas (Individual(s) Involved: Self): Consultant; Astra Zeneca (Individual(s) Involved: Self): Consultant, Grant/Research Support; Bavarian Nordic (Individual(s) Involved: Self): Consultant; BAYER (Individual(s) Involved: Self): Consultant, Grant/Research Support; Blue Earth Diagnostics (Individual(s) Involved: Self): Consultant; Bristol Myers Squbb (Individual(s) Involved: Self): Consultant; Clarity Pharmaceuticals (Individual(s) Involved: Self): Consultant; Clovis Oncology (Individual(s) Involved: Self): Consultant; Constellation (Individual(s) Involved: Self): Consultant, Consultant, Grant/Research Support, Grant/Research Support; Dendreon (Individual(s) Involved: Self): Consultant; EMD Serono (Individual(s) Involved: Self): Consultant; Endocyte (Individual(s) Involved: Self): Grant/Research Support; Fusion Pharma LLC (Individual(s) Involved: Self): Consultant; invitae (Individual(s) Involved: Self): Grant/Research Support; Isotopen Technologien München (Individual(s) Involved: Self): Consultant; Jannsen (Individual(s) Involved: Self): Consultant, Grant/Research Support; Lantheus (Individual(s) Involved: Self): Grant/Research Support; Merck (Individual(s) Involved: Self): Consultant, Grant/Research Support; Moyvant (Individual(s) Involved: Self): Consultant; Myriad (Individual(s) Involved: Self): Consultant; Noria Therapeutics (Individual(s) Involved: Self): Consultant; Novartis Pharmaceuticals (Individual(s) Involved: Self): Consultant; Noxopharm (Individual(s) Involved: Self): Consultant; Pfizer Inc (Individual(s) Involved: Self): Consultant; POINT Biopharma (Individual(s) Involved: Self): Consultant; Progenics (Individual(s) Involved: Self): Consultant, Grant/Research Support; sanofi genzyme (Individual(s) Involved: Self): Consultant; Telix (Individual(s) Involved: Self): Consultant; Tenebio (Individual(s) Involved: Self): Consultant, Grant/Research Support; Theragnostics (Individual(s) Involved: Self): Consultant
Thursday, March 10, 2022
2:50 PM – 3:35 PM
Friday, March 11, 2022
9:30 AM – 11:10 AM
Friday, March 11, 2022
9:35 AM – 9:55 AM
Friday, March 11, 2022
10:02 AM – 10:09 AM
Friday, March 11, 2022
10:09 AM – 10:15 AM
Friday, March 11, 2022
11:20 AM – 12:55 PM
Friday, March 11, 2022
12:05 PM – 12:25 PM
Friday, March 11, 2022
12:25 PM – 12:55 PM
Friday, September 30, 2022
12:15 PM – 12:45 PM
Friday, September 30, 2022
1:59 PM – 2:05 PM
Friday, September 30, 2022
2:05 PM – 2:30 PM
Friday, September 30, 2022
12:10 PM – 2:30 PM
Friday, September 30, 2022
3:25 PM – 3:45 PM
Friday, September 30, 2022
3:45 PM – 4:10 PM
Friday, September 30, 2022
2:40 PM – 4:15 PM